KP772

KP772 is an experimental lanthanum-based coordination complex, specifically tris(1,10-phenanthroline)lanthanum(III) trichloride, developed by researchers at the University of Vienna. It is characterized as an MDR-selective agent, meaning it exhibits enhanced toxicity toward cancer cells that have acquired multidrug resistance (MDR) through the overexpression of the ABCB1 (P-glycoprotein) efflux pump. This phenomenon, termed collateral sensitivity, allows KP772 to effectively target tumor cells that have become resistant to conventional chemotherapies or targeted agents like nintedanib. Preclinical studies have demonstrated its potential in treating various solid tumors, including small cell and non-small cell lung cancers, by inducing apoptosis and bypassing common resistance mechanisms.

Other names

tris(1,10-phenanthroline)lanthanum(III) trichloride